Actually, I think the market's response to Ion Torrent has been more than 'lukewarm'. So far they've been delivering on their promise of 10x improvements every 6 months (which looks to continue for the next 12 months; after that, not so sure). I'm not too keen on IT's strong 'self-promotion', but their technology does seem decent. MiSeq, of course, is top notch. It will really be a question of whether or not it can continue to compete with IT on price.
As for ONT, they dropped a bit of a bombshell today - their first product will be based on the 'strand sequencing' method which ILMN does NOT have the marketing rights for. Looks like ONT will be trying to market their first product on their own. If they're successful, they may not look to ILMN (or anyone else) for help.
<<not sure what you and your cronies are doing is legal, i'll let the SEC decide...>>
Hahahahahahaha. You mean buying shares in an issue that you are short. We're all gaffawing over here. Thanks for the chuckle.
if this drags on for 100 days that would be $1 million in interest expense... not bad if you can get Roche to up the price by $5/share - which I doubt very much.
not sure what you and your cronies are doing is legal, i'll let the SEC decide...
let's not exaggerate. if you and your cronies bought all 3 million shares that were sold today that would be about $25,000 in interest expense to borrow the money for 3,000,000 shares at 6% interest rate. of course you don't need to buy all 3 million shares to prop up the market. likewise you need to keep this up for as long as Roche is interested. so far, it's only been 5 days. so figure about $10k/day carrying costs...
If everything goes as planned another very good earnings report....
Illumina reaffirmed the preliminary unaudited Q4 fiscal year financial results disclosed on January 10, including Q4 revenue of approximately $250M and EPS of 34c per share. Also as disclosed previously, the company reaffirmed its expectation that it will meet or exceed equity analyst estimates for 2012 and will resume providing guidance on its Q4 earnings call. In light of the commencement of Roche’s unsolicited tender offer, Illumina announced that it will postpone its previously scheduled Q4 and fiscal earnings announcement. The company expects to issue results concurrent with the board’s completion of its review of Roche’s unsolicited tender offer and the issue of its recommendation. :theflyonthewall.com